Michael Parke, DO
Family Medicine · Lansdale, PANPI 1033105382
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,423 of the $6,811 with a category attached, or 79.6%. 37 manufacturers reported payments, led by Eli Lilly at 26.7% of the total. Reporting peaked in 2019 at $2,941 and has fallen 71.3% since, to $844 in 2025. Among family medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 310 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2K
- AbbVie$730
- Amgen$493
- Novo Nordisk$421
- AstraZeneca$418
- Merck$390
- plus $3K from 31 others
Across 16 payments — averaging $7267.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$116K
What the payments were for
- Travel & lodging$1,38820%
- Food & beverage$5,42380%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 29 | $1,819 |
| AbbVie(2 entities) | 37 | $730 |
| Amgen | 20 | $493 |
| Novo Nordisk | 22 | $421 |
| AstraZeneca | 25 | $418 |
| Merck | 30 | $390 |
| Pfizer | 31 | $363 |
| Lilly USA, LLC | 10 | $224 |
| Johnson & Johnson(2 entities) | 16 | $201 |
| Exact Sciences | 9 | $187 |
| Daiichi Sankyo Inc. | 10 | $183 |
| Astellas Pharma US Inc | 7 | $152 |
| Biohaven Pharmaceuticals, Inc. | 3 | $148 |
| Sanofi-aventis U.S. LLC | 7 | $131 |
| Sunovion Pharmaceuticals Inc. | 8 | $116 |
| Boehringer Ingelheim | 5 | $105 |
| Amarin Pharma, Inc. | 6 | $96 |
| Abbott | 4 | $75 |
| Eisai Inc. | 5 | $72 |
| GSK | 3 | $48 |
| Sun Pharmaceutical Industries Inc. | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Biofire Diagnostics, LLC | 1 | $35 |
| BD | 1 | $34 |
| Radius Health, Inc. | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $32 |
| Novartis | 2 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Clarus Therapeutics Inc. | 1 | $20 |
| Alk-abello, Inc | 1 | $19 |
| Grifols USA, LLC | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$238
- NURTEC ODT$115
How this compares
$6,811 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $38,343 |
| MounjaroTirzepatide | 26 | $27,023 |
| EliquisApixaban | 21 | $19,253 |
| JardianceEmpagliflozin | 18 | $13,699 |
| JanuviaSitagliptin Phosphate | 12 | $11,260 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,860 |
| Pantoprazole Sodium | 117 | $3,909 |
| Celecoxib | 14 | $2,495 |
| Atorvastatin Calcium | 179 | $2,419 |
| Rosuvastatin Calcium | 157 | $2,296 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,248 |
| Levothyroxine Sodium | 158 | $2,083 |
| SynthroidLevothyroxine Sodium | 17 | $1,629 |
| Metoprolol Succinate | 69 | $1,289 |
| Simvastatin | 88 | $1,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $421 | $38,34343 claims |
| Lilly USA, LLCMounjaro | $224 | $27,02326 claims |
| PfizerEliquis | $363 | $19,25321 claims |
| Boehringer IngelheimJardiance | $105 | $13,69918 claims |
| MerckJanuvia | $390 | $11,26012 claims |
| GSKTrelegy Ellipta | $48 | $7,86012 claims |
| AbbVieSynthroid | $730 | $1,62917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Lansdale
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.